# iBio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/iBio, Inc.). ## Overview iBio, Inc. is a U.S.-based preclinical biotechnology company focused on discovering and developing precision antibodies for cardiometabolic and obesity-related diseases. The company uses an AI and machine learning drug discovery platform, and it also develops and licenses early-stage biologic candidates and related intellectual property. ## Products & services • AI Drug Discovery Platform for hard-to-drug biologics • Precision antibody programs in cardiometabolic disease • Obesity-focused biologic candidates • IBIO-600 preclinical program • IBIO-610 / Activin E program • Collaborative research and licensing services - **AI Drug Discovery Platform** (10%) — Computational platform used to identify and optimize novel biologics and precision antibodies. - **Preclinical Antibody Programs** (55%) — Early-stage therapeutic candidates such as IBIO-600 and IBIO-610 aimed at cardiometabolic and obesity targets. - **Licensing and Collaboration Revenue** (20%) — Revenue from research services, licenses, and partner collaborations tied to discovery assets. - **Intellectual Property and Platform Assets** (15%) — Owned patents, know-how, and related assets that support development and partnering. - AI Drug Discovery Platform for hard-to-drug biologics - Precision antibody programs in cardiometabolic disease - Obesity-focused biologic candidates - IBIO-600 preclinical program - IBIO-610 / Activin E program - Collaborative research and licensing services ## Customers iBio’s direct customers are typically pharmaceutical and biotechnology partners that license programs, fund collaborations, or receive research services tied to its discovery platform. Its end markets are ultimately patients and physicians in cardiometabolic, obesity, and other therapeutic areas, but near-term monetization depends on partnering with larger drug developers. The company also relies on specialized suppliers and contract service providers to support discovery and preclinical work. - **Pharmaceutical licensing partners** (primary) — Large or mid-sized drug companies that may license iBio candidates or IP to advance development and commercialization. - **Biotechnology collaborators** (primary) — Smaller biotech firms or research groups that collaborate on discovery, validation, or target-specific programs. - **Research services customers** (secondary) — Counterparties that pay for collaborative research, assay work, or related services tied to platform capabilities. - **Future therapeutic end users** (emerging) — Patients and clinicians in cardiometabolic and obesity indications who would use approved products if programs succeed. - Pharma partners that license early-stage biologic assets - Biotech collaborators seeking AI-enabled discovery support - Research partners buying services tied to specific programs - Future commercial partners for obesity and cardiometabolic assets - Specialized vendors and CRO/CDMO-type service providers ## Geography iBio is headquartered in the United States and conducts its research and development primarily in San Diego. The company also uses third-party suppliers and collaborators, including international vendors, to support discovery and preclinical work. Its therapeutic programs are described as worldwide in scope, so future partnering and commercialization could extend beyond the U.S. - United States is the operational base and primary R&D location - San Diego facilities house core research and lab activity - Worldwide licensing rights support global partnering potential - Third-party suppliers include U.S. and non-U.S. vendors - No meaningful country revenue disclosure was provided ## Strategy iBio’s strategy is to advance a small number of preclinical antibody programs while using its AI platform to generate differentiated molecules for hard-to-drug targets. It also seeks collaborations and licenses that can monetize discovery assets before internal products reach commercialization. The company’s direction is shaped by the need to convert platform science into partnerable programs and longer-duration therapeutic value. - **Advance preclinical pipeline assets** (short-term) — Pipeline programs are the main source of future value and partnering leverage. - **Expand AI-driven discovery output** (medium-term) — The platform is intended to generate novel biologics that can be licensed or developed. - **Secure collaborations and licenses** (medium-term) — Partnerships can fund development and create non-dilutive value from early assets. - Advance IBIO-600 and IBIO-610 through preclinical development - Use AI/ML to identify differentiated biologics for difficult targets - Pursue collaborations and licensing to monetize discovery assets - Retain worldwide rights where possible for future commercialization - Build internal capabilities while still using external suppliers ## Risks iBio faces the typical risks of an early-stage biotech company: clinical and preclinical failure, regulatory uncertainty, and dependence on external capital and partners. Its platform and assets may never produce meaningful revenue, and the company is exposed to supplier concentration, IP impairment risk, and competitive pressure from better-funded drug developers. - **Development-stage program failure** [critical] — The company is still preclinical, so scientific or translational setbacks could eliminate asset value. - **Capital access and dilution** [high] — Long-duration R&D requires external funding before product revenue is available. - **Partner and collaborator dependence** [high] — Some programs rely on licensees or collaborators to advance development and commercialization. - **Supplier and outsourcing concentration** [medium] — Key materials and services are outsourced and may have long lead times or limited alternatives. - **Competitive and regulatory pressure** [high] — Larger biotech and pharma firms have more resources for R&D, trials, and approvals. - Preclinical programs may fail before reaching clinical proof-of-concept - Additional financing may be needed to fund long development timelines - Partner dependence can limit control over timing and commercialization - Supplier reliance creates lead-time and sourcing risk for critical inputs - IP and intangible assets may be impaired if assumptions weaken ## Accounting The most important accounting judgments for iBio are the valuation of indefinite-lived intangible assets, the treatment of collaboration revenue, and the estimation of fair value assumptions used in impairment testing. Because the company is preclinical and has limited product revenue, small changes in assumptions about future success, discount rates, or partner activity can materially affect reported results. - **Indefinite-lived intangible asset impairment** — Could create non-cash impairment charges and affect equity value - **Collaboration and license revenue recognition** — Can cause uneven quarterly revenue - **Fair value estimates and WACC** — Affects asset carrying values and impairment conclusions - **R&D expense classification** — Influences operating loss and comparability across periods - Indefinite-lived intangible impairment depends on success and discount-rate assumptions - Collaboration revenue may be recognized unevenly as services are delivered - Low revenue base makes quarterly comparisons highly sensitive to small contracts - Fair value estimates can change with stock price, FDA progress, and market rates - R&D and outside-service spending drive most operating expense variability --- *Last updated: 2026-04-29T05:12:21.702252+00:00*